Polio Vaccination in Developing Countries

PEDIATRICS ◽  
1971 ◽  
Vol 48 (4) ◽  
pp. 667-668
Author(s):  
Roy E. Brown ◽  
Michael Katz

We have recently come across the Letter to the Editor from Dr. Shanti Ghosh,1 commenting on the trivalent oral polio virus vaccine trials reported by Hardy, et al. in Pediatrics.2 Although 96 to 100% of infants demonstrated satisfactory levels of immunity in Hardy's group, using a microneutralization titer technique, Dr. Ghosh describes disappointing results in children in India and Nigeria as indicated by low seroconversion rates, as well as very low enterovirus excretion rate in pre- and postimmunization specimens (7.8%).

PEDIATRICS ◽  
1996 ◽  
Vol 98 (4) ◽  
pp. 795-795
Author(s):  
Sanford Schneider

The pro and con commentaries by Drs Judelsohn and Katz (Pediatrics 1996;98:115-117) do not mention projected costs. In these days of limited resources, the greatest bang for the buck is important and perhaps is becoming the most important factor of delivery of medical services to large populations. Developing a single product multi-vaccine containing inactivated polio virus, to be followed by oral live virus vaccine, will unquestionably add to the cost of protection. Also, Dr Katz does not seem to address the problem of compliance.


PEDIATRICS ◽  
1971 ◽  
Vol 47 (3) ◽  
pp. 632-633
Author(s):  
Shanti Ghosh

I was interested to read the paper on trivalent oral polio virus vaccine trials by Hardy and colleagues in your journal of March 1970,1 which reached here only recently. It prompts me to state the results we have achieved in the babies attending the Well Baby Clinic, who received three doses of trivalent oral polio vaccine at 4 to 6 weeks interval beginning at 3 to 6 months of age.2 Our results are disappointing and compare with the results achieved in some other tropical countries, particularly Nigeria.


BMJ ◽  
2014 ◽  
Vol 349 (dec10 5) ◽  
pp. g7518-g7518 ◽  
Author(s):  
S. E. Bellan ◽  
J. R. C. Pulliam ◽  
J. Dushoff ◽  
L. A. Meyers

Author(s):  
Gulay Korukluoglu ◽  
Umit Ozdemirer ◽  
Fatma Bayrakdar ◽  
Zehra Unal ◽  
Yasemin Cosgun ◽  
...  

AbstractPoliomyelitis was a disease feared worldwide, striking suddenly and paralysing mainly children for life. Monitoring of suspected cases of poliomyelitis is carried out with Acute Flaccid Paralysis (AFP) surveillance in Turkey. This study examines national data of AFP surveillance and the epidemiology of enteroviruses (EV) in Turkey from 2000 to 2019 and gives an overview of the detected serotypes of EVs. A total of 13,640 samples collected from patients with 5216 AFP pre-diagnosed cases (2 samples from each patient) and 3,208 contacts, during a 20-year period (2000–2019) were investigated. All isolated polioviruses were tested for their wild or vaccine origin according to the WHO recommended protocol by PCR and sequencing analysis were performed. Enterovirus positivity was detected in a total of 915 cases, which were identified as 204 Sabin-like polio virus (SLPV) and 711 non-polio enterovirus (NPEV). Of the 204 SLPV, 141 (69.1%) AFP were detected in patients and 63 (30.9%) were detected in samples taken from their contacts. Of the 711 NPEVs, 516 (72.5%) were from AFP cases and 195 (27.5%) were detected in samples taken from their contacts. It is concluded that the reason for the higher detection rate of NPEV in samples from AFP pre-diagnosed cases is attributed to the polio vaccination rates reaching 97% between 2008 and 2019 in Turkey. The most frequently detected NPEV serotypes were Coxackie A24, B3, and Echo 30. This retrospective study is the first comprehensive study in Turkey to evaluate the results of the AFP surveillance in the last 20 years.


1959 ◽  
Vol 76 (5) ◽  
pp. 74
Author(s):  
Helen Buechl
Keyword(s):  

Vaccine ◽  
2014 ◽  
Vol 32 (42) ◽  
pp. 5460-5467 ◽  
Author(s):  
Bethany White ◽  
Annie Madden ◽  
Maria Prins ◽  
Margaret Hellard ◽  
Handan Wand ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document